According to el molecular biologist, Osvaldo Luis Podhjacer the The anticovid vaccine developed by the Fundación Instituto Leloir and the CONICET of Argentina neutralizes the Delta, Gamma and Alpha variants of the Covid-19 pandemic.
“These studies were done with isolated cells and What we saw is that the sera of animals immunized with a vaccine generated against the initial variant in the region called D614G also neutralizes the new variants with great efficiency, “explained Podhjacer from Buenos Aires.
The biologist heads a group of researchers from the Leloir Institute and the National Council for Scientific and Technical Research (CONICET) in the development of the vaccine called Corovax G3.
Likewise, Podhjacer said that they are advancing together with the Malbrán Institute, dependent on the Ministry of Health, in the preclinical regulatory studies of the absence of toxicity of the vaccine and is being studied with the company Mabxience, which produces AstraZeneca for Latin America, the formulation and analytical aspects of the Argentine inoculant.
The scientist added that they are improving the Corovax G3 in order to anticipate new variants that may emerge now and in the near future.
“In this way we could vaccinate the population with a broader spectrum vaccine“said Podhjacer when asked about the advances in the development of the Argentine vaccine against the pandemic.
The Leloir Institute and CONICET plan to test the vaccine in humans at the end of this year or the beginning of 2022 as long as they get financial funds to face this phase.
–
According to el molecular biologist, Osvaldo Luis Podhjacer the The anticovid vaccine developed by the Fundación Instituto Leloir and the CONICET of Argentina neutralizes the Delta, Gamma and Alpha variants of the Covid-19 pandemic.
“These studies were done with isolated cells and What we saw is that the sera of animals immunized with a vaccine generated against the initial variant in the region called D614G also neutralizes the new variants with great efficiency, “explained Podhjacer from Buenos Aires.
The biologist heads a group of researchers from the Leloir Institute and the National Council for Scientific and Technical Research (CONICET) in the development of the vaccine called Corovax G3.
Likewise, Podhjacer said that they are advancing together with the Malbrán Institute, dependent on the Ministry of Health, in the preclinical regulatory studies of the absence of toxicity of the vaccine and is being studied with the company Mabxience, which produces AstraZeneca for Latin America, the formulation and analytical aspects of the Argentine inoculant.
The scientist added that they are improving the Corovax G3 in order to anticipate new variants that may emerge now and in the near future.
“In this way we could vaccinate the population with a broader spectrum vaccine“said Podhjacer when asked about the advances in the development of the Argentine vaccine against the pandemic.
The Leloir Institute and CONICET plan to test the vaccine in humans at the end of this year or the beginning of 2022 as long as they get financial funds to face this phase.
;
–
